Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Arthritis Care & Research|May 11, 2021
General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled TrialsFrancis Berenbaum, Thomas J Schnitzer, Alan J Kivitz, et al.
Journal of Clinical Medicine|April 13, 2023
Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and SatisfactionThomas J Schnitzer, Rebecca L Robinson, Lars Viktrup, et al.
Journal of Pain Research|December 31, 2020
Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United StatesSrinivas R Nalamachu, Rebecca L Robinson, Lars Viktrup, et al.
Seminars in Arthritis and Rheumatism|April 8, 2020
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration studyThomas J Schnitzer, Arifulla Khan, Louis Bessette, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?Philip G Conaghan, Michael J Doane, Dena Hirschfield Jaffe, et al.
The Journal of Urology|October 8, 2013
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasiaAdolfo Casabé, Claus G Roehrborn, Luigi F Da Pozzo, et al.
Advances in Rheumatology (London, England)|April 22, 2024
Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritisThomas J Schnitzer, Philip G Conaghan, Francis Berenbaum, et al.
Arthritis Care & Research|March 18, 2025
Association of Pain During Exercise With Exercise-Induced Hypoalgesia in People With Knee OsteoarthritisSoyoung Lee, Tuhina Neogi, Benjamin M Senderling, et al.
Clinical Drug Investigation|July 17, 2023
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with OsteoarthritisMark T Brown, David R Cornblath, Martin Koltzenburg, et al.
Neurourology and Urodynamics|February 2, 2011
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionKarl-Erik Andersson, William C de Groat, Kevin T McVary, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Arthritis Care & Research|May 11, 2021
General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled TrialsFrancis Berenbaum, Thomas J Schnitzer, Alan J Kivitz, et al.
Journal of Clinical Medicine|April 13, 2023
Opioids for Osteoarthritis: Cross-Sectional Survey of Patient Perspectives and SatisfactionThomas J Schnitzer, Rebecca L Robinson, Lars Viktrup, et al.
Journal of Pain Research|December 31, 2020
Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United StatesSrinivas R Nalamachu, Rebecca L Robinson, Lars Viktrup, et al.
Seminars in Arthritis and Rheumatism|April 8, 2020
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration studyThomas J Schnitzer, Arifulla Khan, Louis Bessette, et al.
Clinical and Experimental Rheumatology|September 8, 2020
Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?Philip G Conaghan, Michael J Doane, Dena Hirschfield Jaffe, et al.
The Journal of Urology|October 8, 2013
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasiaAdolfo Casabé, Claus G Roehrborn, Luigi F Da Pozzo, et al.
Advances in Rheumatology (London, England)|April 22, 2024
Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritisThomas J Schnitzer, Philip G Conaghan, Francis Berenbaum, et al.
Arthritis Care & Research|March 18, 2025
Association of Pain During Exercise With Exercise-Induced Hypoalgesia in People With Knee OsteoarthritisSoyoung Lee, Tuhina Neogi, Benjamin M Senderling, et al.
Clinical Drug Investigation|July 17, 2023
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with OsteoarthritisMark T Brown, David R Cornblath, Martin Koltzenburg, et al.
Neurourology and Urodynamics|February 2, 2011
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of actionKarl-Erik Andersson, William C de Groat, Kevin T McVary, et al.
Pageof 12